IKT.US Inhibikase Therapeutics Inc

Healthcare Biotechnology USA Stocks
1.52 USD
Close of Nov 15, 2026
1.40 2.61
Market cap
USD 213M
P/E
-
P/B
1.13x
ROE
-39.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IKT.US undervalued?

Graham number

The Graham number of Inhibikase Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Inhibikase Therapeutics Inc fundamental analysis

No fundamental analysis for Inhibikase Therapeutics Inc yet.

Inhibikase Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Inhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PA…

Full company profile